Gan & Lee Pharmaceuticals banner

Gan & Lee Pharmaceuticals
SSE:603087

Watchlist Manager
Gan & Lee Pharmaceuticals Logo
Gan & Lee Pharmaceuticals
SSE:603087
Watchlist
Price: 67.02 CNY 1.25%
Market Cap: ¥40B

Relative Value

The Relative Value of one Gan & Lee Pharmaceuticals stock under the Base Case scenario is hidden CNY. Compared to the current market price of 67.02 CNY, Gan & Lee Pharmaceuticals is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Gan & Lee Pharmaceuticals Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Gan & Lee Pharmaceuticals Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Gan & Lee Pharmaceuticals
SSE:603087
40.1B CNY 10.4 43.3 52.8 52.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
402.2B USD 6.7 171.3 16.6 23.5
US
Astria Therapeutics Inc
NASDAQ:ATXS
326.4B USD 462 374.5 -2 631.9 -2 389.6 -2 389.6
US
Amgen Inc
NASDAQ:AMGN
206.8B USD 5.6 26.9 15.3 15.3
US
Gilead Sciences Inc
NASDAQ:GILD
182.9B USD 6.2 21.5 14.6 14.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.6B USD 10.2 31.1 23.8 24.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.3B USD 5.8 18.5 14 15.9
NL
argenx SE
XBRU:ARGX
43.3B EUR 14.3 33.5 57.4 59
AU
CSL Ltd
ASX:CSL
70.7B AUD 3.2 16.6 11.4 14.2
P/S Multiple
Revenue Growth P/S to Growth
CN
Gan & Lee Pharmaceuticals
SSE:603087
Average P/S: 3 105 036.4
10.4
28%
0.4
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
10%
0.7
US
Astria Therapeutics Inc
NASDAQ:ATXS
462 374.5
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
5.6
3%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
6.2
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
10%
0.6
NL
argenx SE
XBRU:ARGX
14.3
49%
0.3
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
P/E Multiple
Earnings Growth PEG
CN
Gan & Lee Pharmaceuticals
SSE:603087
Average P/E: 45.3
43.3
44%
1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171.3
89%
1.9
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 631.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
26.9
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
21.5
14%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
17%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.5
13%
1.4
NL
argenx SE
XBRU:ARGX
33.5
42%
0.8
AU
CSL Ltd
ASX:CSL
16.6
11%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Gan & Lee Pharmaceuticals
SSE:603087
Average EV/EBITDA: 25.7
52.8
90%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 389.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.3
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
18%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
15%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14
23%
0.6
NL
argenx SE
XBRU:ARGX
57.4
810%
0.1
AU
CSL Ltd
ASX:CSL
11.4
8%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Gan & Lee Pharmaceuticals
SSE:603087
Average EV/EBIT: 27.5
52.8
80%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 389.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.3
2%
7.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.8
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
21%
0.8
NL
argenx SE
XBRU:ARGX
59
N/A N/A
AU
CSL Ltd
ASX:CSL
14.2
11%
1.3
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett